We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+50.39%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$3.65B
AUM Growth
+$1.23B
Cap. Flow
+$333M
Cap. Flow %
9.14%
Top 10 Hldgs %
23.51%
Holding
147
New
14
Increased
82
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$36.8M
2
UNH icon
UnitedHealth
UNH
+$30.1M
3
RPRX icon
Royalty Pharma
RPRX
+$24.7M
4
NVAX icon
Novavax
NVAX
+$21.8M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$19.5M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$42.7M
2
ISRG icon
Intuitive Surgical
ISRG
+$17.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.7M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.68M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 96.99%
2 Miscellaneous 1.37%
3 Consumer Staples 1.09%
4 Consumer Discretionary 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAS
126
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$5.26M 0.14%
1,143,925
+18,925
+2% +$83.8K
GRTX
127
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.05M 0.11%
567,552
+67,552
+14% +$717K
NARI
128
DELISTED
Inari Medical, Inc. Common Stock
NARI
$3.88M 0.11%
+80,000
New +$3.82M
CO
129
DELISTED
Global Cord Blood Corporation
CO
$2.87M 0.08%
925,000
– –
ACRS icon
130
Aclaris Therapeutics
ACRS
$813M
$2.66M 0.07%
1,644,015
+44,015
+3% +$59K
FPRX
131
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.48M 0.07%
406,729
+6,729
+2% +$27.7K
CYTK icon
132
Cytokinetics
CYTK
$9.64B
$1.82M 0.05%
+77,417
New +$1.45M
NBRV
133
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$720K 0.02%
4,271
+71
+2% +$11.8K
BMY.RT
134
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$663K 0.02%
185,150
– –
TMO icon
135
Thermo Fisher Scientific
TMO
$237B
– –
-17,500
Closed -$4.96M
AXNX
136
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-125,000
Closed -$3.18M
XLRN
137
DELISTED
Acceleron Pharma
XLRN
– –
-17,500
Closed -$1.57M
FTSV
138
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-447,400
Closed -$42.7M
2 3 4 5
6

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Rock Springs Capital Management held 147 positions worth $3.65B, up 51% from $2.42B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $333M of net new capital in Q2 2020, opening 14 new positions and adding to 82 existing holdings. Its largest new stake was Royalty Pharma: 500,000 shares worth $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Intuitive Surgical, an estimated $17.5M trimmed.

  • Rock Springs Capital Management's largest Q2 2020 buy was Royalty Pharma: 500,000 shares worth $24.3M.
  • Rock Springs Capital Management added most to Centene in Q2 2020, an estimated $36.8M increase.
  • Rock Springs Capital Management's biggest Q2 2020 reduction was Intuitive Surgical, cutting an estimated $17.5M.
  • Rock Springs Capital Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $42.7M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $3.65B portfolio in Q2 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 4 in Q2 2020.
  • Rock Springs Capital Management's portfolio value rose 51% quarter-over-quarter to $3.65B.

Based on Rock Springs Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.